These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18632639)

  • 1. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
    Hwang JY; Mangala LS; Fok JY; Lin YG; Merritt WM; Spannuth WA; Nick AM; Fiterman DJ; Vivas-Mejia PE; Deavers MT; Coleman RL; Lopez-Berestein G; Mehta K; Sood AK
    Cancer Res; 2008 Jul; 68(14):5849-58. PubMed ID: 18632639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
    Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
    J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
    Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
    Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
    Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
    J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.
    Shao M; Cao L; Shen C; Satpathy M; Chelladurai B; Bigsby RM; Nakshatri H; Matei D
    Cancer Res; 2009 Dec; 69(24):9192-201. PubMed ID: 19951993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin.
    Sima LE; Yakubov B; Zhang S; Condello S; Grigorescu AA; Nwani NG; Chen L; Schiltz GE; Arvanitis C; Zhang ZY; Matei D
    Mol Cancer Ther; 2019 Jun; 18(6):1057-1068. PubMed ID: 31015308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
    Cao L; Petrusca DN; Satpathy M; Nakshatri H; Petrache I; Matei D
    Carcinogenesis; 2008 Oct; 29(10):1893-900. PubMed ID: 18667446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity.
    Satpathy M; Shao M; Emerson R; Donner DB; Matei D
    J Biol Chem; 2009 Jun; 284(23):15390-9. PubMed ID: 19324884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.
    Yakubov B; Chelladurai B; Schmitt J; Emerson R; Turchi JJ; Matei D
    Neoplasia; 2013 Jun; 15(6):609-19. PubMed ID: 23730209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
    Herman JF; Mangala LS; Mehta K
    Oncogene; 2006 May; 25(21):3049-58. PubMed ID: 16449978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.
    Verma A; Guha S; Diagaradjane P; Kunnumakkara AB; Sanguino AM; Lopez-Berestein G; Sood AK; Aggarwal BB; Krishnan S; Gelovani JG; Mehta K
    Clin Cancer Res; 2008 Apr; 14(8):2476-83. PubMed ID: 18413840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
    Mehta K; Fok J; Miller FR; Koul D; Sahin AA
    Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells.
    Mangala LS; Fok JY; Zorrilla-Calancha IR; Verma A; Mehta K
    Oncogene; 2007 Apr; 26(17):2459-70. PubMed ID: 17043648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells.
    Chen SH; Lin CY; Lee LT; Chang GD; Lee PP; Hung CC; Kao WT; Tsai PH; Schally AV; Hwang JJ; Lee MT
    Anticancer Res; 2010 Oct; 30(10):4177-86. PubMed ID: 21036738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
    Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
    Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.
    Khanna M; Chelladurai B; Gavini A; Li L; Shao M; Courtney D; Turchi JJ; Matei D; Meroueh S
    Mol Cancer Ther; 2011 Apr; 10(4):626-36. PubMed ID: 21330459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
    Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.
    Satpathy M; Cao L; Pincheira R; Emerson R; Bigsby R; Nakshatri H; Matei D
    Cancer Res; 2007 Aug; 67(15):7194-202. PubMed ID: 17671187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.